Maternal Serum Osteopontin Levels in Pregnant Women Diagnosed With PPROM (OPN)

PRETERM LABOR (1)

The study group included pregnant women with a diagnosis of preterm premature rupture of membranes (PPROM) confirmed by clinical and/or diagnostic tests. The diagnosis was confirmed by observing the discharge of amniotic fluid from the cervical os during a sterile speculum examination and, when necessary, by confirmatory diagnostic tests. The study included pregnant women without additional systemic diseases and with blood pressure measurements within the normal range.

Diagnosetest: SERUM OSTEOPONTİN

At the time of diagnosis, 5 mL venous blood samples were collected from all participants for biochemical analysis. The samples were centrifuged at 3,000 rpm for 10 minutes to separate the serum, which was then stored at -80°C until analysis. Serum osteopontin levels were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) kit (Human Osteopontin ELISA Kit, Cat. No: E1525Hu, BT Laboratory, China) in accordance with the manufacturer's protocol.

This kit has been developed for the quantitative determination of osteopontin levels in serum, plasma, and other biological fluids. The assay principle is based on the pre-coating of microplate wells with an antibody specific to human SPP1. The osteopontin present in the samples was incubated with a biotinylated secondary antibody and a streptavidin-horseradish peroxidase (HRP) complex after binding to this antibody. Following the washing steps, a substrate solution was added, and the resulting color reaction was stopped with an ac

Andere Namen:

• OSTEOPONTİN

Control /Term labor (2)

The control group included pregnant women with a singleton pregnancy who experienced membrane rupture at 37 weeks + 0 days of gestation or later, had no signs of active infection and no history of additional systemic diseases. It was confirmed that none of these cases had a history of membrane rupture prior to the 37th week of gestation. The control group was selected from volunteers who met the eligibility criteria at the time of their admission to the delivery ward, and written informed consent was obtained after they were informed about the study.

Diagnosetest: SERUM OSTEOPONTİN

At the time of diagnosis, 5 mL venous blood samples were collected from all participants for biochemical analysis. The samples were centrifuged at 3,000 rpm for 10 minutes to separate the serum, which was then stored at -80°C until analysis. Serum osteopontin levels were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) kit (Human Osteopontin ELISA Kit, Cat. No: E1525Hu, BT Laboratory, China) in accordance with the manufacturer's protocol.

This kit has been developed for the quantitative determination of osteopontin levels in serum, plasma, and other biological fluids. The assay principle is based on the pre-coating of microplate wells with an antibody specific to human SPP1. The osteopontin present in the samples was incubated with a biotinylated secondary antibody and a streptavidin-horseradish peroxidase (HRP) complex after binding to this antibody. Following the washing steps, a substrate solution was added, and the resulting color reaction was stopped with an ac

Andere Namen:

• OSTEOPONTİN

Maternal Serum Osteopontin Concentration

Description: Concentration of osteopontin (ng/mL) measured in maternal serum using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (e.g., Human Osteopontin ELISA Kit, manufacturer name and catalog number to be specified). Blood samples are collected at the time of diagnosis of PPROM or term membrane rupture, within 48 hours before delivery.

Unit of Measure: ng/mL (nanograms per milliliter) Time Frame: 48 hours (from diagnosis to sample collection) Reporting Metric: Mean osteopontin concentration (with standard deviation) will be reported for each group (PPROM and term membrane rupture). Between-group comparison will be performed using an appropriate statistical test (e.g., independent t-test or Mann-Whitney U test).